Thus, our current and previous findings49 position PIMT as a novel therapeutic target for T2D and given the significance of the ERK-mediated Ser298 phosphorylation of PIMT in glucose metabolism, strategies may be designed to specifically inhibit ERK-mediated PIMT phosphorylation for improved glucose homeostasis. The gene discussed is MAPK1; the disease is type 2 diabetes mellitus.